J44.9 C34.9
Conditions
Interventions
Group 1: Patients with COPD (disease stage III-IV according to FEV1, corresponding to 20 kg/m2, no weight loss >5 % in the last 12 months
Cross-sectional examination with structured anamnesis, clinica
Sponsors
LMU Klinikum, Medizinische Klinik und Poliklinik V
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - underlying disease currently assumed to be stable, no emergency treatment with hospitalization >24 h in the last 4 weeks - no antibiotic or hematopoietic (G-CSF) treatment in the last 4 weeks - patient is able to read and answer questionnaires - patient is able to perform lung function and diffusion measurement - Patient able to perform a hand force measurement
Exclusion criteria
Exclusion criteria: - patient age <18 years, patient not capable of giving informed consent - unclear primary diagnosis (e.g.: suspected COPD, inclusion in the study can be reconsidered if the diagnosis is confirmed) -severe known comorbidity associated with the development of cachexia, e.g. second malignancy, HIV infection (exception: concomitant COPD in NSCLC) - Lack of weight gain during childhood development with a long-term low BMI <20 kg/m2 - known serious eating disorder, e.g. anorexia nervosa - currently desired weight loss, e.g. as part of a diet - anamnestic or documented Covid-19 infection within the last month - pregnancy - known critical anemia (Hb <8 g/dl) - known high-grade cardiac arrhythmia - known or documented allergy to nonivamide/nicobixil, as well as electrode patches - after implantation of automatic, electronic devices, e.g. pacemakers - after heart transplantation, lung transplantation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Creation of a multimodal data set for comparative, explorative analyses of cachexia in COPD and NSCLC as a basis for a longitudinal follow-up study | — |
Secondary
| Measure | Time frame |
|---|---|
| Identification of possible anamnestic and clinical predictors for the occurrence of cachexia in COPD and NSCLC | — |
Countries
Germany
Contacts
Public ContactThomas Melzer
LMU Klinikum, Medizinische Klinik und Poliklinik V
Outcome results
None listed